Temocapril

Temocapril
	File:Temocapril.svg
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	C09AA14 (WHO) ;
Identifiers
	IUPAC name 2-[(2S)-6-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid;
CAS Number	111902-57-9;
PubChem CID	71323;
ChemSpider	64431;
UNII	18IZ008EU6;
KEGG	D08566 check;
ChEMBL	ChEMBL2110627;
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).;
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C23H28N2O5S2
Molar mass	476.61 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC(=O)[C@H](CCc1ccccc1)NC2CS[C@@H](CN(C2=O)CC(=O)O)c3cccs3;
	InChI InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18?,20-/m0/s1; Key:FIQOFIRCTOWDOW-DXCJPMOASA-N;
	(verify)

Temocapril (also known as temocaprilum [Latin]; brand name Acecol) is an ACE inhibitor. It was not approved for use in the US.

It is administered as inactive prodrug, then converted to its active metabolite, temocaprilat.^[1]

It was patented in 1984 and approved for medical use in 1994.^[2]

References

^ Yasunari, K., Maeda, K., Nakamura, M., Watanabe, T., Yoshikawa, J., & Asada, A. (2004). Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile. Cardiovascular drug reviews, 22(3), 189–198. https://doi.org/10.1111/j.1527-3466.2004.tb00140.x
^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

This stereochemistry article is a stub. You can help Wikipedia by expanding it.

v t e Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril (+nebivolol) Dicarboxylate-containing: Enalapril^# (+lercanidipine, +nitrendipine) Benazepril (+amlodipine, +pimobendan) Cilazapril Delapril (+manidipine) Imidapril Lisinopril (+amlodipine, +HCT) Moexipril Perindopril (+amlodipine, +bisoprolol, +indapamide, +amlodipine and indapamide, +bisoprolol and amlodipine, +bisoprolol, amlodipine, and indapamide) Quinapril (+HCT) Ramipril (+amlodipine, +amlodipine and HCT, +bisoprolol, +felodipine) Spirapril Temocapril Trandolapril (+verapamil) Phosphonate-containing: Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan (+amlodipine, +amlodipine and HCT) Eprosartan Fimasartan Irbesartan (+amlodipine, +amlodipine and HCT, +HCT) Losartan (+amlodipine, +HCT) Olmesartan (+amlodipine, +amlodipine and HCT, +HCT) Tasosartan^§ Telmisartan (+amlodipine, +amlodipine and HCT, +amlodipine and indapamide, +HCT) Valsartan (+aliskiren, +amlodipine, +amlodipine and HCT, +HCT, +lercanidipine, +nebivolol, +sacubitril)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +HCT, +amlodipine and HCT) Remikiren^§
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
Other	Sparsentan
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III